Clinical Trial Update: Proof of Principle Study to Evaluate the Safety, PK, Viral Shedding and Efficacy of Pentarlandir™ UPPTA for Patients With Early COVID-19 [Phase 2]

View source ↗

Summary

Phase 2 proof-of-principle trial evaluating safety, pharmacokinetics, viral shedding, and efficacy of Pentarlandir UPPTA for early COVID-19.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronavirus Disease 2019

Drugs mentioned

• Pentarlandir UPPTA (UPPTA)

Snippet

Sponsor: SyneuRx International (Taiwan) Corp | Conditions: Coronavirus Disease 2019 | Phase 2 | Status: UNKNOWN